Drug news
NICE recommends Zytiga (Janssen Cilag) for metastatic Prostate Cancer
The National Institute for Health and Clinical Excellence (NICE) has published final guidance endorsing Zytiga (abiraterone acetate) from Janssen Cilag as an NHS treatment option for patients in England and Wales with metastatic castration resistant Prostate Cancer (mCRPC), if their disease has progressed despite having received a docetaxel-containing chemotherapy regimen.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.